Aveanna Healthcare (AVAH) Q2 2026 Earnings Call Transcript

Aveanna reported Q2 revenue of $670.5M (+13.7% YoY) and adjusted EBITDA of $95.4M (+8% YoY), citing improved reimbursement rates, volume, and operational efficiencies. The company raised 2026 guidance to revenue >$2.68B (from $2.63B–$2.65B) and adjusted EBITDA >$365M (from $338M–$342M), while also improving capital structure via a 75 bps term-loan repricing to cut annual interest expense by ~$10M. Management lifted long-term organic growth outlooks—Private Duty Services to 5%–6% (from 3%–5%) and Home Health & Hospice to 8%–10% (from 5%–7%)—driven by state rate improvements including a legislated California PDN rate increase effective Jan. 1, 2027 and progress on preferred payer agreements (e.g., 64% preferred-payer MCO volume for Private Duty Services).

Analysis

AVAH is less a classic earnings beat than a proof-of-concept that reimbursement wins can be converted into labor supply, and labor supply converts into durable volume. The important second-order effect is that scale now matters more than ever: if you can front-run wages, onboard faster, and process payer agreements, you can pull demand out of the system before smaller rivals can react. That makes the moat wider in practice than in headline revenue growth.

The near-term market is likely to underwrite the wrong variable: wages may step up before reimbursement fully flows, so Q4-1H27 can look noisier than the long-run unit economics justify. Still, the company’s cash generation and reduced interest burden mean the equity is no longer just a leveraged turnaround; it is starting to behave like a self-funding consolidator. That should favor the stock over 6-18 months if management keeps deleveraging while integrating acquisitions.

The contrarian risk is that consensus is extrapolating too cleanly from rate wins to margin expansion. The real test is whether California and the other higher-rate states actually unlock fill-rate improvement by Q1-Q2 2027; if not, the wage pass-through becomes a cash drag and multiple support fades. A second falsifier is acquisition discipline: if M&A slows deleveraging or if the company pays up for growth, the rerating case weakens quickly.

Key Decisions for Investors

• Buy AVAH on any post-earnings pullback and hold for 6-12 months; the thesis is not this quarter’s guide, but 2027 volume conversion and FCF compounding. Falsify if California fill rates do not improve meaningfully by Q1-Q2 2027 or if organic growth stalls below the updated long-run framework.
• Avoid chasing AVAH after an initial gap-up; the better entry is after the market digests the near-term wage-pass-through headwind that can temporarily mask margin leverage in Q4. Use weakness to build the position rather than paying for perfect execution.
• Set a hard watch item on the late-September California rate finalization and the next two quarters of admissions/fill rates. If the state update lands but staffing does not inflect by year-end, treat the story as a labor bottleneck rather than a structural growth re-rate.
• For relative value, prefer AVAH over slower-growth home-health or hospice exposures that lack a similar reimbursement catalyst; if you need a hedge, use a broad healthcare-services short rather than a direct pair, since the main edge is execution leverage, not pure sector beta.